Microcap Ledger Abvc Biopharma, Inc. $ABVC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
This page is still filling in. We publish more sections as filings are processed.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Fremont, CA
- Fiscal year end
- December 31
- Shares outstanding
- 26,654,365 [10-Q 2026-08-12]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$2.30M | −$1.14M | $31.9K | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $296.0K | −$7.91M | −$2.99M | $681.5K | [10-K 2026-03-03] |
| FY ended Dec 2024 | $509.6K | −$4.90M | −$1.81M | $248.4K | [10-K 2026-03-03] |
- Quarterly cash burn
- −$569.3K
- Cash runway Estimate
- ~0.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-13 | 12,975,492 | [10-Q 2024-11-14] |
| 2025-04-11 | 15,778,305 | [10-K 2025-04-15] |
| 2025-04-30 | 16,773,261 | [10-Q 2025-04-30] |
| 2025-08-12 | 23,541,824 | [10-Q 2025-08-13] |
| 2025-10-30 | 24,301,089 | [10-Q 2025-11-03] |
| 2026-03-03 | 25,440,407 | [10-K 2026-03-03] |
| 2026-05-14 | 26,000,442 | [10-Q 2026-05-18] |
| 2026-08-10 | 26,654,365 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2025-05-22; no effectiveness notice found in EDGAR [S-3 2025-05-22]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-04-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-30] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-29 | DEF 14A | Proxy statement |
| 2026-08-27 | 8-K | Material agreement entered; Acquisition or disposition completed; Regulation FD disclosure |
| 2026-08-17 | 424B4 | Prospectus or prospectus supplement |
| 2026-08-17 | 424B4 | Prospectus or prospectus supplement |
| 2026-08-17 | 424B4 | Prospectus or prospectus supplement |
| 2026-08-17 | 424B4 | Prospectus or prospectus supplement |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-08-12 | 8-K | Other events |
| 2026-08-04 | 8-K | Other events |
| 2026-07-28 | PRE 14A | Proxy statement |
| 2026-07-02 | 8-K | Auditor change |
| 2026-05-18 | 10-Q | Quarterly report |
Alerts for $ABVC
Email me when Abvc Biopharma, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.